The United States Court of Appeals for the First Circuit recently upheld the dismissal of a securities fraud case against Apellis Pharmaceuticals, Inc. The court ruled that the company's statements regarding its drug SYFOVRE were not misleading, a decision that affects investors and the biopharmaceutical industry. The case, titled In Re: Apellis Pharmaceuticals, Inc. Securities Litigation (Docket No. 25-1383), highlights the complexities of securities fraud claims and the standards required for such allegations.
The plaintiffs in this case, Ray Peleckas and the Michigan Laborers’ Pension Fund, alleged that Apellis and its CEO, Dr. Cedric Francois, made materially misleading statements about the results of clinical trials for SYFOVRE, a drug approved by the Food and Drug Administration (FDA) for treating geographic atrophy. The plaintiffs claimed that the defendants' public statements omitted crucial information about the trials, leading investors to believe that the drug was safer than it actually was. The court's ruling is significant as it clarifies the legal standards for proving securities fraud.
The dispute began when Peleckas and the pension fund filed a putative class action in August 2023 in the U.S. District Court for the District of Delaware. They sought to represent all purchasers of Apellis common stock from January 28, 2021, to July 28, 2023. The case was later transferred to the U.S. District Court for the District of Massachusetts to meet venue requirements. The plaintiffs argued that the defendants' statements about the absence of retinal vasculitis cases in clinical trials were misleading because the trials were not designed to detect such conditions.
Apellis is a biopharmaceutical company that developed pegcetacoplan, marketed as SYFOVRE, to treat geographic atrophy, a severe form of age-related macular degeneration. Although SYFOVRE does not improve vision, it aims to slow the progression of the disease. The FDA approved the drug on February 17, 2023. However, following reports of retinal vasculitis cases associated with SYFOVRE, Apellis's stock price dropped significantly. The plaintiffs contended that the company failed to disclose that its clinical trials did not adequately test for retinal vasculitis, which they claimed constituted securities fraud.
The court ruled on August 19, 2026, affirming the district court's dismissal of the case. The judges, including Circuit Judges Aframe, Lynch, and Kayatta, agreed that the plaintiffs did not provide sufficient evidence to support their claims. The court stated, "We agree that the challenged statements cannot plausibly be viewed as materially misleading and affirm on that basis without ruling on the issue of scienter." The ruling emphasized that the plaintiffs failed to demonstrate that the defendants' statements were misleading due to omissions regarding the clinical trial protocols.
The court highlighted that the protocols for the OAKS and DERBY trials, which were publicly available, included requirements for administering fluorescein angiograms to test for retinal vasculitis. The plaintiffs argued that the trials did not require prompt follow-up tests for participants showing symptoms of retinal vasculitis. However, the court found that the defendants had adequately disclosed the testing protocols and that no retinal vasculitis cases were reported among trial participants.
The impact of this ruling is significant for investors and the biopharmaceutical industry. It sets a precedent regarding the level of disclosure required in clinical trial reporting and the standards for proving securities fraud. The court's decision reinforces that companies must provide accurate information about their products and clinical trials but are not required to disclose every potential risk if they have already provided sufficient information. This ruling may deter similar lawsuits against biopharmaceutical companies in the future, as it clarifies the legal thresholds for proving misleading statements.
Looking ahead, the plaintiffs could potentially appeal the ruling, but details were not available in the court filing regarding any plans for further legal action. The outcome of this case may influence future securities litigation involving biopharmaceutical companies and their disclosures during clinical trials.